RECRUITINGOBSERVATIONAL
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）
A Study on Multimodal Data Prediction of Outcome to Neoadjuvant Therapy in NSCLC
About This Trial
This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC. The core research question is: Can a multi-model approach predict outcomes of neoadjuvant therapy for non-small cell lung cancer and provide clinical recommendations?
Who May Be Eligible (Plain English)
Who May Qualify:
1. pathologically diagnosed non-small cell lung cancer
2. The treatment plan is：receiving neoadjuvant chemo-immunotherapy during the study period, followed by surgical resection
Who Should NOT Join This Trial:
1. recurrent or metastatic lung cancer;
2. patients with other primary tumors
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. pathologically diagnosed non-small cell lung cancer
2. The treatment plan is：receiving neoadjuvant chemo-immunotherapy during the study period, followed by surgical resection
Exclusion Criteria:
1. recurrent or metastatic lung cancer;
2. patients with other primary tumors
Locations (2)
Tongji hospital
Wuhan, Hubei, China
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China